ERBB2 and breast carcinoma: Since this study primarily focused on demonstrating the feasibility of establishing PDX-derived breast cancer cell lines and the basic characteristics of these cell lines, we only tested the most commonly used drugs in HER2+ and triple-negative breast cancer cells—lapatinib and paclitaxel, respectively.